NUVALENT INC-A
NUVLNASDAQTrading Snapshot
- Day Range
- $122.13 β $124.48
- 52-Week Range
- $71.13 β $123.99
- Volume
- $2.33B
- Avg Volume
- $1.65B
- Shares Outstanding
- 73.7M
- Next Earnings
- Nov 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $3.38B
- Last Q Revenue
- $769M
- P/E Ratio
- -20.5
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-5.72
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +5.6%
Why Investors Own NUVL
- βHigh-growth profile β revenue up +22.0% YoY with expanding US Equity exposure.
- βHealthy economics β 36% gross margin and 20% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NUVALENT INC-A
NUVL
StockOtter Β· stockotter.spaceAbout NUVALENT INC-A
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
Fifth Third Bancorp Acquires New Holdings in Nuvalent, Inc. $NUVL
Fifth Third Bancorp bought a new position in shares of Nuvalent, Inc. (NASDAQ: NUVL) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The insti
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq β PSNL), Distribution Solutions Group, Inc. (Nasdaq β DSGR), Cross Country Healthcare, Inc. (Nasdaq β CCRN), Nuvalent, Inc. (Nasdaq β NUVL)
BALA CYNWYD, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq β ATAI), Distribution Solutions Group, Inc. (Nasdaq β DSGR), Cross Country Healthcare, Inc. (Nasdaq β CCRN), Nuvalent, Inc. (Nasdaq β NUVL)
BALA CYNWYD, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (Γ’ΒΒKSFΓ’ΒΒ) are investigating the propo
Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Nuvalent (NASDAQ: NUVL) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with GSK plc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq β NUVL), Dana Incorporated (NYSE β DAN), SUNation Energy, Inc. (Nasdaq β SUNE), Taylor Morrison Home Corporation (NYSE - TMHC),
BALA CYNWYD, Pa., June 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith